Certain confidential information contained in this document, marked by [***], has been omitted because such information is both not material and is the type that the Company customarily and actually treats that as private or confidential. Exhibit 10.9

Amendment Number Two Agreement

This Amendment Agreement (the “Number Two Agreement”) is entered into as indicated below, among National Institutes for Quantum and Radiological Science and Technology (“QST”), a research institute in Japan, having an address at 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba 263-8555, Japan, APRINOIA Therapeutics Inc. (“APRINOIA TW”), a corporation of Taiwan, having an address at 17F., No.3, Park St., Nangang Dist., Taipei City 11503, Taiwan and APRINOIA Therapeutics Inc. (“APRINOIA KY”), a corporation of Cayman Islands, having an address at The Grand Pavilion Commercial Centre, Oleander Way, 802 West Bay Road, P.O. Box 32052, Grand Cayman KY1-1208, Cayman Islands, in consideration of the mutual agreement to make alterations to the Exclusive License Agreement (the “Original Agreement”) executed on October 20^th, 2016 by QST and APRINOIA TW and the Amendment Agreement (the “Number One Agreement”) executed on January 11^th ,2018 by QST, APRINOIA TW and APRINOIA KY.

1. DEFINITIONS

Unless otherwise agreed in the Number Two Agreement, the terms used in this Number Two Agreement shall adhere to the definitions in the Original Agreement.

1

2. CHANGE OF THE PARTIES

This Number Two Agreement shall change the term for APRINOIA being a party changed by the Number One Agreement, as provided below:

Before	APRINOIA Therapeutics Inc. (“APRINOIA”), a corporation of Cayman Islands, having an address at The Grand Pavilion Commercial Centre, Oleander Way, 802 West Bay Road, P.O. Box 32052, Grand Cayman KY1-1208, Cayman Islands
After	APRINOIA Therapeutics Inc. (“APRINOIA”), a corporation of Taiwan, having an address at 17F., No.3, Park St., Nangang Dist., Taipei City 11503, Taiwan(R.O.C)

3. GENERAL

3.1 This Number Two Agreement shall become effective as of June-1, 2019.

3.2 This Number Two Agreement is drafted in both English and Japanese. If there is any discrepancy between the English and Japanese versions, the English version shall prevail.

3.2 Except as expressly provided for alterations herein, the provisions in the Original Agreement and the Number One Agreement shall remain in effect.

2

In witness whereof, QST, APRINOIA TW and APRINOIA KY have executed this Agreement in three (3) originals by its duly authorized officer or representative.

National Institutes for Quantum and Radiological Science and Technology (QST)

Representative: HIRANO Toshio 

Title: President 

Address: 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba 263-8555, Japan

Signature: /s/ HIRANO Toshio

Date: May 27, 2019

APRINOIA Therapeutics Inc. (APRINOIA TW) 

Representative: Ming-Kuei Jang, Ph.D. 

Title: Cheif Executive Officer 

Address: 17E, No.3, Park St., Nangang Dist., Taipei City 11503, Taiwan

Signature: /s/ Ming-Kuei Jang, Ph.D.

Date: June 12 2019

3

APRINOIA Therapeutics Inc. (APRINOIA KY) 

Representative: Ming-Kuei Jang, Ph.D. 

Title: Chairman 

Address: The Grand Pavilion Commercial Centre, Oleander Way, 802 West Bay Road, P.O. Box 32052, Grand Cayman KY1-1208, Cayman Islands

Signature: /s/ Ming-Kuei Jang, Ph.D.

Date: June 12 2019

4